Researchers are investigating a little-known protein fragment called P3 that may form harmful clumps and contribute to brain-cell damage. The findings could broaden our understanding of Alzheimer’s disease, although its role in patients remains uncertain.
For decades, much of the search for an effective Alzheimer’s treatment has focused on a familiar suspect: amyloid beta, a protein fragment that accumulates in the brains of people with the disease.
But what if another, closely related molecule has been receiving far less attention than it deserves?
New research highlighted by the University of California, Santa Cruz, is drawing attention to a small protein fragment called P3. Once widely regarded as relatively harmless, P3 has been shown in laboratory research to form clumps and threadlike structures resembling those associated with other amyloid proteins. Researchers have also reported evidence that it may harm neurons and interact with amyloid beta.
The findings, discussed in a research perspective published in the journal ChemBioChem, raise a question that could matter for future Alzheimer’s research: have scientists been overlooking part of the molecular picture?
The answer is not yet clear. There is no evidence that P3 alone causes Alzheimer’s disease in humans, and the latest publication is not a clinical trial or a demonstration of a new treatment. Nevertheless, it challenges an assumption about how this peptide behaves and points to a potential avenue for further investigation.
Here is what researchers have discovered, why it matters, and what it could mean for the future of Alzheimer’s treatment.
What is the overlooked P3 peptide?
P3 is a short fragment produced when the body processes a much larger protein called amyloid precursor protein, or APP.
APP is found in cell membranes, including those of neurons. The body naturally cuts this protein into smaller pieces through several biochemical pathways. What happens next depends partly on which enzymes perform those cuts.
One pathway produces amyloid beta, the fragment most commonly associated with Alzheimer’s research. Another begins with an enzyme called alpha-secretase and can produce P3 after further processing by gamma-secretase.
For years, P3 was often described as non-amyloidogenic, meaning it was not expected to form the kinds of protein aggregates associated with amyloid diseases. It was also frequently regarded as relatively harmless to cells.
Chemistry professor Jevgenij Raskatov at UC Santa Cruz and his colleagues questioned whether those assumptions were justified.
Their work suggests that P3 can assemble into larger structures known as oligomers and fibrils. Oligomers are groups of molecules joined together, while fibrils are elongated structures formed through the organization of protein fragments.
These structures matter because abnormal protein aggregation is a recurring feature of several neurodegenerative diseases.
In his 2026 research perspective, Raskatov argues that P3 deserves closer examination rather than being automatically dismissed as an irrelevant by-product of normal protein processing.
The paper is available in ChemBioChem, published by Wiley, and its full text can also be read through PubMed Central.
Why amyloid beta has dominated Alzheimer’s research
To understand why P3 is attracting attention, it helps to look at the history of the amyloid hypothesis.
Amyloid beta can accumulate in the brain and form plaques outside nerve cells. Genetic evidence has strongly connected abnormal amyloid processing with certain inherited forms of Alzheimer’s disease, helping establish amyloid beta as a central target for drug development.
For years, researchers have investigated treatments designed to reduce its production, prevent its aggregation or remove it from the brain.
This work has produced important advances, although the overall history has been complicated. Many experimental drugs failed to demonstrate meaningful benefits, while newer antibody treatments have shown that targeting amyloid can modestly slow cognitive and functional decline in selected people with early Alzheimer’s disease.
For example, the US Food and Drug Administration has approved lecanemab and donanemab for eligible patients with early symptomatic Alzheimer’s disease. These medicines are not cures, and they carry important risks that require medical assessment and monitoring.
The US Food and Drug Administration’s information on lecanemab explains the regulatory basis for its traditional approval.
These developments make the P3 question particularly interesting. If researchers have concentrated heavily on amyloid beta while overlooking another fragment capable of forming aggregates, could that fragment help explain some of the complexity that has frustrated drug development?
Possibly, but this remains a research hypothesis rather than an established explanation for the limitations of Alzheimer’s treatments.
Amyloid beta remains an important part of the disease’s biology. The new work does not establish that scientists should abandon it.
What did the new research actually discover?
The latest attention surrounding P3 comes from a research perspective that brings together findings from several investigations, rather than from a single large clinical study.
The researchers report that P3 can form oligomers and fibrils under experimental conditions. They also describe evidence that the peptide can interact physically with amyloid beta, potentially changing how the two molecules aggregate and how toxic the resulting structures may be.
One reason this matters is that P3 lacks a portion of the amyloid beta sequence that contributes to the latter’s interactions with water. This difference may affect how readily the fragments remain dissolved and how they assemble into larger structures.
Researchers have reported that P3 can aggregate rapidly in laboratory experiments. They have also found evidence that it may be toxic to neurons, although its toxicity appears lower than that of amyloid beta in the experimental systems examined.
The findings challenge the assumption that P3 is necessarily harmless simply because it is produced through a different processing pathway.
However, laboratory aggregation does not automatically establish disease causation. Conditions inside a test tube can differ substantially from the environment in a living human brain, where proteins interact with many other molecules and are subject to biological clearance mechanisms.
The critical next step is to establish whether P3 accumulates in the brains of people with Alzheimer’s disease, in what quantities, and whether those levels are associated with disease progression.
Could P3 damage brain cells?
Neurons depend on a carefully regulated internal environment. Their ability to communicate, transport essential materials and maintain their structure can be disrupted by abnormal protein interactions.
Amyloid beta and tau are two proteins central to current models of Alzheimer’s disease. Amyloid beta can form extracellular plaques, while tau can accumulate abnormally inside neurons, forming tangles associated with neuronal dysfunction.
Researchers are investigating whether P3 might add another layer to this process.
If P3 forms aggregates in the brain, those structures could potentially interfere with cellular functions or interact with amyloid beta in ways that influence its behaviour. The research literature also raises possible mechanisms involving cell membranes, oxidative stress and inflammation.
These mechanisms have not all been established as causes of Alzheimer’s disease in humans. They remain possible explanations that require further testing.
It is also important to distinguish between evidence that a molecule can damage cells under experimental conditions and evidence that it causes progressive cognitive decline in people.
The latter requires much more than identifying an interesting biochemical property. Researchers need evidence from human tissue, reliable methods to measure the molecule in the brain, and studies linking its presence to clinical outcomes.
At present, P3 is a potential contributor worthy of investigation—not a confirmed hidden cause of Alzheimer’s disease.
What about tau and brain inflammation?
P3 is not the only area of Alzheimer’s research moving beyond a simple focus on amyloid plaques.
Tau has long been recognised as another central component of the disease. Under normal conditions, tau helps stabilise microtubules, structures that support the internal organisation and transport systems of neurons. In Alzheimer’s disease, tau can become abnormally modified, detach from its normal locations and accumulate in aggregates.
The relationship between amyloid beta and tau remains an active area of investigation. Researchers are studying how one protein may influence the behaviour of the other and why some brain regions experience more severe damage than others.
Inflammation is another important part of the picture. The brain contains immune-related cells, including microglia, that help remove cellular debris and respond to injury. These cells can be protective, but persistent or poorly regulated immune activity may contribute to neuronal damage.
A 2026 study published in Nature Neuroscience investigated how immune cells activated outside the brain may contribute to tau-associated neurodegeneration. The findings suggest that immune pathways could influence brain damage, although the work does not establish a proven treatment for people with Alzheimer’s disease.
Together, these research directions illustrate why Alzheimer’s is increasingly understood as a complex biological process involving multiple interacting mechanisms.
Amyloid beta, tau, inflammation, cellular stress and protein clearance may all contribute in different ways and at different stages of the disease. Their relative importance may also vary between individuals.
P3 could eventually become part of this broader picture, but its contribution has yet to be established.
Does this mean scientists were wrong about amyloid beta?
Not necessarily.
Scientific understanding changes as new evidence emerges, and a molecule once considered unimportant can turn out to have biological properties worth investigating. That does not mean the entire body of research built around another molecule was mistaken.
Amyloid beta has substantial evidence supporting its role in Alzheimer’s disease. Genetic studies, brain imaging, biomarker research and clinical trials all contribute to the current understanding of its significance.
The fact that amyloid-targeting drugs produce limited benefits does not, by itself, prove that amyloid beta is irrelevant. It may mean that removing plaques after the disease has begun cannot reverse all the damage, that treatment timing matters, or that other processes continue to drive progression.
P3 offers another possible avenue for understanding this complexity.
Raskatov’s work argues that future research should investigate whether P3 is present in Alzheimer’s-related deposits and whether it interacts with amyloid beta in living brains. Measuring the two fragments separately is challenging because P3 is structurally related to amyloid beta.
Better analytical methods could help determine whether P3 is merely present alongside other disease-related proteins or whether it contributes independently to the process.
That distinction is essential. Detecting a molecule in diseased tissue is not the same as demonstrating that it causes the disease.
Could this discovery lead to a new Alzheimer’s treatment?
It is too early to say.
If future studies establish that P3 contributes meaningfully to Alzheimer’s pathology, researchers might explore several possibilities. These could include developing molecules that prevent harmful aggregation, modifying the biological pathways that produce P3, or investigating whether changing interactions between P3 and amyloid beta affects neuronal health.
But each possibility comes with unanswered questions.
P3 is generated through normal protein processing, so interfering with its production could affect other biological functions. Researchers would need to establish whether targeting it is safe, whether it reaches the relevant parts of the brain and whether changing its behaviour produces a measurable benefit.
Before any P3-targeted treatment could be recommended to patients, it would need to progress through appropriate preclinical studies and clinical trials.
There is currently no approved Alzheimer’s treatment specifically designed to target P3, and no evidence that supplements, dietary changes or existing medicines can selectively eliminate it from the brain.
For patients and families, the practical message remains unchanged: established medical evaluation and evidence-based care are essential. Experimental findings should not be used as a reason to stop prescribed medication or delay seeking professional advice.
The National Institute on Aging’s Alzheimer’s disease resource provides reliable information about symptoms, diagnosis, treatment and ongoing research.
What scientists need to investigate next
Several questions will determine whether P3 becomes an important part of Alzheimer’s research.
First, scientists need better evidence that the peptide accumulates in the brains of people with the disease. This requires sensitive methods that can distinguish P3 from related protein fragments.
Second, researchers need to determine whether its presence correlates with the severity or progression of Alzheimer’s disease. Studies comparing affected brain tissue with appropriate controls could help establish whether P3 is associated with the disease in humans.
Third, experiments need to clarify how P3 behaves alongside amyloid beta and tau, including whether it changes their aggregation, toxicity or distribution.
Finally, researchers must determine whether manipulating P3 changes disease-related outcomes in suitable experimental models. Even a convincing biological mechanism would need further validation before it could guide treatment decisions.
These questions will take time to answer. Alzheimer’s is a complex, progressive condition, and discoveries at the molecular level do not always translate into effective medicines.
Nevertheless, identifying a previously underappreciated biological process can help researchers ask better questions and design more informative experiments.
The bigger picture: Alzheimer’s may involve more than one culprit
The emerging research on P3 highlights a broader lesson about neurodegenerative disease: the molecules involved in normal biology can behave differently depending on how they are processed, where they accumulate and what they interact with.
For years, P3 was commonly treated as a relatively harmless product of APP processing. Newer experimental evidence suggests that this view may be too simplistic.
That is an important reason to investigate it further. It is not yet evidence that P3 is the missing explanation for Alzheimer’s disease, nor does it establish that targeting the peptide will prevent memory loss.
The strongest conclusion is also the most scientifically useful one: Alzheimer’s research should continue examining how amyloid beta, tau, inflammation and other molecular processes interact, rather than assuming that a single mechanism explains every stage of the disease.
If further studies confirm that P3 contributes to brain-cell damage in patients, the discovery could broaden the range of targets researchers investigate.
For now, P3 remains a promising research question—not a proven cause or a ready-made cure. The next breakthroughs will depend on demonstrating what the peptide actually does inside the human brain, and whether changing its behaviour can improve outcomes for people living with Alzheimer’s disease.
